The emerging pipeline of CAR-T in NHL includes late-stage, mid-stage, and early-stage drugs in different lines of therapies and different indications, mainly including B- cell Lymphoma such as DLBCL, FL, MCL, MZL, CLL/SLL, and others, with one of them being developed for a T-cell Lymphoma, PTCL.
LAS VEGAS, April 15, 2024 /PRNewswire/ — DelveInsight’s CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Insights report includes a comprehensive understanding of current treatment practices, CAR T-Cell Therapy for NHL emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan].
Key Takeaways from the CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Report
- According to DelveInsight’s analysis, the market size for CAR T-Cell therapy for NHL reached USD 1,200 million in 2023 across the US.
- DelveInsight’s analysis reveals that the total incident cases of selected indications for CAR-T in NHL in the 7MM comprised ~155,200 in 2023.
- Leading CAR T-Cell therapy for NHL companies such as Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Mustang Bio, CRISPR Therapeutics, 2seventy Bio, Imugene, and others are developing novel CAR T-Cell therapies for NHL drugs that can be available in the CAR T-Cell therapy for NHL market in the coming years.
- Other promising CAR T-Cell therapies for NHL in the pipeline include Cemacabtagene Ansegedleucel, Rapcabtagene Autoleucel, Zamtocabtagene Autoleucel, MB-106, CTX110, BBT369, Azercabtagene Zapreleucel, and others.
- BREYANZI is poised to dominate the CAR-T market in NHL in the forthcoming years, with potential approvals anticipated across two indications: CLL/SLL, follicular lymphoma and MCL. Notably, it has already secured approval for DLBCL in 3L+, 2L+ TE, and NTE.
- Novartis is progressing with its additional CD-19 CAR-T therapy, Rapcabtagene autoleucel, with expectations of a significantly reduced turnaround time for availability compared to KYMRIAH.
- Companies are leveraging the strength of dual and triple targeting in CAR-T therapies. Miltenyi Biomedicine, ImmPACT Bio, 2seventy bio, and Novartis are developing CD19/20 Bispecific CAR-T, CD79a/CD20 Bispecific CAR-T, and CD2xCD3xCD19 CAR-T, enhancing treatment efficacy by targeting multiple antigens simultaneously.
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Overview
CAR-T cell therapy represents a groundbreaking advancement in cancer immunotherapy, especially for specific types of NHL that have shown resistance to traditional therapies. Through the manipulation of genetically modified T cells, this state-of-the-art treatment boosts the immune system’s capacity to locate and eliminate cancerous cells. Essentially, CAR-T cell therapy modifies a patient’s T cells genetically to carry chimeric antigen receptors (CARs) on their surface. These engineered CARs are tailored to identify and attach to particular proteins found on cancer cells’ surfaces, thereby directing the immune system to effectively combat the malignancy.
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Epidemiology Segmentation
In 2023, DLBCL had the highest number of cases among all selected indications for CAR-T therapy, followed by Follicular lymphoma. The total incident cases of MZL in the 7MM were around 13,800 in 2023 and are projected to increase during the forecasted period.
The CAR T-Cell therapy for NHL market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Incident Cases of Selected Indications for CAR-T in NHL (Mantle cell lymphoma, DLBCL, Follicular lymphoma, Marginal Zone Lymphoma, Primary mediastinal large B-cell lymphoma, Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma) and Total Indication-wise Eligible Cases of CAR-T in NHL.
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Treatment Market
The treatment landscape for NHL is complex, influenced by factors such as the type of NHL, the stage of the disease, the patient’s overall health, and their preferences. CAR-T cell therapy has emerged as a promising option within this landscape, especially for aggressive B-cell NHLs that have not responded to standard treatments. Previously, such cases posed significant challenges, often resulting in poor outlooks despite attempts with salvage chemotherapy and autologous stem cell transplants.
However, the introduction of CAR-T cell therapy has drastically changed this scenario, showing impressive response rates and the potential for long-lasting remissions even in patients with advanced disease after multiple prior treatments. The approval of various CAR-T therapies for NHL by the FDA highlights the importance of this advancement. YESCARTA, KYMRIAH, BREYANZI, and TECARTUS have all proven effective across different types of NHL, including DLBCL, follicular lymphoma, and mantle cell lymphoma.
Ongoing research aims to improve CAR-T cell therapy for NHL further, seeking to increase effectiveness, decrease side effects, and expand the range of target antigens beyond CD19. Additionally, studies are looking into the combined use of CAR-T cell therapy with other treatments like checkpoint inhibitors or targeted therapies, with the ultimate goal of optimizing treatment outcomes for NHL patients.
Emerging CAR T-Cell Therapies for NHL and Key Companies
- Cemacabtagene Ansegedleucel: Allogene Therapeutics
- Rapcabtagene Autoleucel: Novartis
- Zamtocabtagene Autoleucel: Miltenyi Biomedicine
- MB-106: Mustang Bio
- CTX110: CRISPR Therapeutics
- BBT369: 2seventy Bio
- Azercabtagene Zapreleucel: Imugene
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Dynamics
The dynamics of the CAR T-Cell therapy for the NHL market are expected to change in the coming years. The market for CAR T-cell therapy in NHL is characterized by a surge in research and development activities, as pharmaceutical companies race to bring new therapies to the market. With several CAR T-cell therapies receiving FDA approval, competition among manufacturers is intense, driving innovation and investment in the field. As a result, we witness a dynamic landscape with ongoing clinical trials, collaborations, and strategic partnerships aiming to expand the reach and efficacy of CAR T-cell therapies for NHL.
Moreover, the market dynamics of CAR T-cell therapy for NHL are influenced by patient accessibility and reimbursement challenges. Despite the remarkable efficacy of these therapies, their high cost poses a significant barrier to widespread adoption. Healthcare systems and insurers grapple with the economic implications of CAR T-cell therapy, leading to negotiations on pricing and reimbursement models. Efforts are underway to make these life-saving treatments more accessible to patients, including discussions on value-based pricing and outcome-based reimbursement. As the field continues to evolve, the CAR T-cell therapy for NHL market dynamics will be shaped by a delicate balance between the clinical benefits of CAR T-cell therapy and the economic considerations surrounding its widespread implementation in the treatment of Non-Hodgkin’s lymphoma.
| CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Report Metrics | Details |
| Study Period | 2019–2032 |
| Coverage | 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. |
| CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market CAGR | ~15% |
| CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Size in 2023 | USD 1,200 Million |
| Key CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Companies | Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Mustang Bio, CRISPR Therapeutics, 2seventy Bio, Imugene, and others |
| Key CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma in Pipeline | Cemacabtagene Ansegedleucel, Rapcabtagene Autoleucel, Zamtocabtagene Autoleucel, MB-106, CTX110, BBT369, Azercabtagene Zapreleucel, and others |
Scope of the CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Report
- Therapeutic Assessment: CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma current marketed and emerging therapies
- CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Dynamics: Key Market Forecast Assumptions of Emerging CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Access and Reimbursement
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Ultragenyx Provides Update on Stage 1 Cohorts in Phase 1/2/3 Cyprus2+ Study for Wilson Disease with AAV9 Gene Therapy
October 3, 2024 NOVATO, Calif. — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced promising results from the ongoing Phase 1/2/3 Cyprus2+ study evaluating UX701 gene therapy for Wilson disease. Early-stage data from Stage 1 of the trial revealed significant...
World-First CAR-T Therapy Using Donor Cells Sends Autoimmune Diseases into Remission
In a groundbreaking advancement, three individuals suffering from severe autoimmune diseases have achieved remission after receiving a revolutionary therapy using donor-derived immune cells. This pioneering treatment, which utilized bioengineered immune cells known as...
Purespring nabs $105M to take gene therapy into the clinic as IgAN field matures
Purespring Therapeutics has reeled in £80 million ($105 million) to test two gene therapies in humans. The Sofinnova Partners-led Series B, disclosed Wednesday morning, will carry the London startup into an open-label Phase 1/2 next year for a kidney disease that has...
A Philadelphia biotech designed a first-of-its-kind therapy for rare cancer: Now, it waits for patients
Credit: Pixabay/CC0 Public DomainWithin the next couple of weeks, the first blood samples from patients will arrive at the loading dock of Adaptimmune, a biotechnology company headquartered on the northeastern edge of the Navy Yard. Their arrival will open a new...
Related Services
Plasmids GMP Services
AAV GMP Services
